Bimekizumab Pregnancy Exposure and Outcome Registry: An OTIS Autoimmune Diseases in Pregnancy Study

Study identification

• EU PAS number:
  EUPAS1000000968
• Study ID:
  1000000968
• Official title and acronym:
  Bimekizumab Pregnancy Exposure and Outcome Registry: An OTIS Autoimmune Diseases in Pregnancy Study
• DARWIN EU® study:
  No
• Study countries:
  Canada

  United States
• Study description:
  No information provided.
• Study status:
  Ongoing

Study timelines

Date when funding contract was signed

Planned:01/03/2022

Actual:01/03/2022

Study start date

Planned:03/10/2024

Actual:03/10/2024

Date of final study report

Planned:30/06/2035

Sources of funding

Pharmaceutical company and other private sector 

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 3 (required)

Other study registration identification numbers and links

PS0036